Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells

被引:58
|
作者
Rajgolikar, G
Chan, KK
Wang, HCR
机构
[1] Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Dev Therapeut Program, Columbus, OH 43210 USA
关键词
anticancer agent; apoptosis; breast cancer cells; FR901228; intracellular signaling pathways;
D O I
10.1023/A:1006091014092
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human breast cancer MCF7 and MDA-MB231 cells were used to investigate the biological and molecular activities of a novel naturally occurring agent, FK901228 (FK), that possesses a potent antitumor activity against hum an and murine tumor cells. Investigation of the cytotoxicity of FR and induction of internucleosomal DNA degradation in FR-treated cultures revealed that FR induced apoptotic-like cell death of MCF7 and MDA-MB231 cells. In FR-treated apoptotic cultures, flow cytometry? revealed that there was a significant decrease of cells in S phase of the cell cycle. In FK-treated ce Ils there was an increased expression of p21(Cip1) and phosphorylation of Bcl-2 as determined by Western immunoblotting, and a novel cytoplasmic kinase of 33 kDa, p33 kinase, as determined by the in-gel kinase assay using myelin basic protein (MBP) as a substrate. Increased expression of P21(Cip1) phosphorylation of Bcl-2 and activation of p33 MBP kinase may play part of the key mechanism for FR-induced apoptosis.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 50 条
  • [1] Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells
    Girish Rajgolikar
    Kenneth K. Chan
    Hwa-Chain R. Wang
    Breast Cancer Research and Treatment, 1998, 51 : 29 - 38
  • [2] FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
    Nakajima, H
    Kim, YB
    Terano, H
    Yoshida, M
    Horinouchi, S
    EXPERIMENTAL CELL RESEARCH, 1998, 241 (01) : 126 - 133
  • [3] Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
    Stacey L. Berg
    Jeffery Stone
    Jim J. Xiao
    Kenneth K. Chan
    Jed Nuchtern
    Robert Dauser
    Leticia McGuffey
    Patrick Thompson
    Susan M. Blaney
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 85 - 88
  • [4] FR901228, A NOVEL ANTITUMOR BICYCLIC DEPSIPEPTIDE PRODUCED BY CHROMOBACTERIUM-VIOLACEUM NO-968 .2. STRUCTURE DETERMINATION
    SHIGEMATSU, N
    UEDA, H
    TAKASE, S
    TANAKA, H
    YAMAMOTO, K
    TADA, T
    JOURNAL OF ANTIBIOTICS, 1994, 47 (03): : 311 - 314
  • [5] Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
    Berg, SL
    Stone, J
    Xiao, JJ
    Chan, KK
    Nuchtern, J
    Dauser, R
    McGuffey, L
    Thompson, P
    Blaney, SM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (01) : 85 - 88
  • [6] Determination of depsipeptide (FR901228) in human plasma by liquid chromatography-tandem mass spectrometry
    Bai, F
    Iacono, LC
    Freeman, BB
    Stewart, CF
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2004, 27 (20) : 3265 - 3278
  • [7] FR901228, a novel antitumor bicyclic depsipeptide, has marked in vitro activity against both the K-562 cell line and human acute leukemia cells.
    Byrd, JC
    Waselenko, JK
    Shinn, CA
    Miller, C
    Gore, S
    Sausville, E
    Grever, MR
    BLOOD, 1997, 90 (10) : 3810 - 3810
  • [8] Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
    Byrd, JC
    Shinn, C
    Ravi, R
    Willis, CR
    Waselenko, JK
    Flinn, IW
    Dawson, NA
    Grever, MR
    BLOOD, 1999, 94 (04) : 1401 - 1408
  • [9] Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma
    Khan, SB
    Maududi, T
    Barton, K
    Ayers, J
    Alkan, S
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) : 156 - 161
  • [10] Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS
    Kenneth K. Chan
    Ray Bakhtiar
    Chun Jiang
    Investigational New Drugs, 1997, 15 : 195 - 206